- Home
- IONS vs AAL Comparison
IONS vs AAL Comparison
Compare IONS & AAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- AAL
- Stock Information
- Founded
- IONS 1989
- AAL 1930
- Country
- IONS United States
- AAL United States
- Employees
- IONS N/A
- AAL N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- AAL Air Freight/Delivery Services
- Sector
- IONS Health Care
- AAL Consumer Discretionary
- Exchange
- IONS Nasdaq
- AAL Nasdaq
- Market Cap
- IONS 6.8B
- AAL 7.8B
- IPO Year
- IONS 1991
- AAL N/A
- Fundamental
- Price
- IONS $70.41
- AAL $13.73
- Analyst Decision
- IONS Strong Buy
- AAL Hold
- Analyst Count
- IONS 20
- AAL 13
- Target Price
- IONS $75.55
- AAL $15.33
- AVG Volume (30 Days)
- IONS 2.1M
- AAL 69.7M
- Earning Date
- IONS 10-29-2025
- AAL 10-23-2025
- Dividend Yield
- IONS N/A
- AAL N/A
- EPS Growth
- IONS N/A
- AAL 115.68
- EPS
- IONS N/A
- AAL 0.90
- Revenue
- IONS $944,050,000.00
- AAL $54,294,000,000.00
- Revenue This Year
- IONS $24.02
- AAL $1.52
- Revenue Next Year
- IONS $4.06
- AAL $6.11
- P/E Ratio
- IONS N/A
- AAL $15.25
- Revenue Growth
- IONS 16.05
- AAL 1.27
- 52 Week Low
- IONS $23.95
- AAL $8.50
- 52 Week High
- IONS $74.42
- AAL $19.10
- Technical
- Relative Strength Index (RSI)
- IONS 63.48
- AAL 68.30
- Support Level
- IONS $70.47
- AAL $11.99
- Resistance Level
- IONS $74.42
- AAL $12.40
- Average True Range (ATR)
- IONS 1.84
- AAL 0.55
- MACD
- IONS -0.64
- AAL 0.19
- Stochastic Oscillator
- IONS 37.12
- AAL 93.32
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About AAL American Airlines Group Inc.
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest fleet of US legacy carriers.